US stock · Healthcare sector · Medical Devices
Company Logo

Glaukos Corporation

GKOSNYSE

51.52

USD
-0.96
(-1.83%)
Market Closed
-27.38P/E
-28Forward P/E
-1.24P/E to S&P500
2.458BMarket CAP
- -Div Yield
Upcoming Earnings
22 Feb
Shares Short
1/13/23
4.47M
Short % of Float
15.80%
Short % of Shares Outs.
9.37%
% Held by Insiders
4.01%
% Held by Institutions
95.98%
Beta
1.20
PEG Ratio
-2.99
52w. high/low
64.49/33.33
Avg. Daily Volume
0.37M
Return %
Stock
S&P 500
1 year
(3.61)
(7.99)
3 years
(14.38)
24.38
5 years
75.84
53.16
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
33.92
18.53
39.82
14.25
52.49
23.07
70.91
25.25
84.65
50.60
76.20
23.31
99.00
39.35
64.49
33.33
53.32
42.48
Currency: USD
- -
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
0.84
1.91
4.10
3.47
4.63
5.13
6.34
5.06
6.29
6.03
Earnings per share
- -
- -
- -
- -
- -
- -
- -
(0.51)
(0.51)
(2.13)
0.14
(0.00)
(0.37)
0.41
(2.70)
(1.06)
(1.90)
FCF per share
- -
- -
- -
- -
- -
- -
- -
(0.57)
(0.33)
(0.18)
0.18
0.56
0.24
(0.14)
(0.67)
(0.49)
(1.38)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
0.03
0.04
0.05
0.19
0.18
0.29
0.13
0.16
1.02
0.66
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
0.60
0.25
5.45
3.56
4.02
4.92
18.02
15.00
12.56
12.15
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
25
24
17
33
34
35
37
44
47
47
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
(12.6)
193.5
(14,440.0)
(122.1)
164.3
(17.9)
(65.0)
(27.4)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.6)
8.7
(612.1)
(4.9)
6.8
(0.5)
(2.2)
(1.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
21
46
72
114
159
181
237
225
294
285
Operating margin
- -
- -
- -
- -
- -
- -
- -
(67.8)%
(28.9)%
(14.4)%
3.7%
(1.4)%
(7.2)%
(21.2)%
(54.9)%
(11.2)%
(22.7)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
1
4
4
5
5
6
10
35
34
36
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
(13)
(12)
(37)
5
(0)
(13)
15
(120)
(50)
(90)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
(0.0)%
(0.1)%
(0.1)%
0.9%
9,300.0%
(4.7)%
130.8%
9.0%
(0.7)%
1.7%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
(60.3)%
(26.6)%
(51.9)%
4.0%
(0.1)%
(7.1)%
6.5%
(53.5)%
(16.9)%
(30.8)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
6
(10)
84
103
123
146
205
420
423
388
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
18
9
1
- -
- -
- -
73
271
382
383
Equity (m)
- -
- -
- -
- -
- -
- -
- -
15
6
95
117
138
174
673
667
587
549
ROIC
- -
- -
- -
- -
- -
- -
- -
(37.2)%
(72.8)%
(37.6)%
4.4%
(3.0)%
(7.3)%
1.9%
(11.2)%
(3.7)%
(7.9)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
(31.9)%
(31.5)%
(31.0)%
3.8%
0.0%
(6.0)%
(5.8)%
(11.8)%
(3.4)%
(7.5)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
(84.8)%
(199.4)%
(39.1)%
3.9%
(0.1)%
(7.4)%
2.3%
(18.0)%
(8.4)%
(16.3)%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
4 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 460
Total assets
$ 1,008
Long-term debt
$ 383
Cash and equiv.
$ 104
Goodwill
$ 66
Retained earnings
$ (433)
Common stock
48
Enterprise Value
$ 2,736
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
174
404
414
Receivables
38
36
33
Inventory
43
16
23
Other
8
47
54
Current assets
263
469
486
Acc. Payable
6
4
7
Debt due
- -
- -
- -
Other
52
45
56
Current liabilities
58
50
63
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
30.70%
17.55%
- -
Cash flow
(22.88)%
62.40%
- -
Earnings
(58.79)%
3,204.76%
- -
Dividends
- -
- -
- -
Book value
(12.03)%
75.04%
- -
Insider Trading
Type
Shares
Date
Burns Thomas William
InKind
721
01/26/23
Burns Thomas William
InKind
1,802
01/26/23
Navratil Tomas
InKind
356
01/26/23
Navratil Tomas
InKind
885
01/26/23
Navratil Tomas
InKind
389
01/11/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
55
32
65
73
225
2021
68
78
75
73
294
2022
68
73
71
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.21)
(0.90)
(0.35)
(0.24)
(2.70)
2021
(0.35)
(0.37)
0.13
(0.47)
(1.06)
2022
0.11
(0.96)
(0.58)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Thomas Burns
Full-time employees:
727
City:
San Clemente
Address:
229 Avenida Fabricante
IPO:
Jun 25, 2015
Website:
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.